Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ISRG 
Intuitive Surgical Inc (ISRG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/10/2025: ISRG (5-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
33 Analysts rated it
Highly popular stock, broad analyst coverage, trusted insights, strong investor interest.
1 Year Target Price $575.49
1 Year Target Price $575.49
| 14 | Strong Buy |
| 8 | Buy |
| 10 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 83.41% | Avg. Invested days 80 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 07/10/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 189.29B USD | Price to earnings Ratio 76.87 | 1Y Target Price 575.49 |
Price to earnings Ratio 76.87 | 1Y Target Price 575.49 | ||
Volume (30-day avg) 33 | Beta 1.68 | 52 Weeks Range 413.82 - 616.00 | Updated Date 07/10/2025 |
52 Weeks Range 413.82 - 616.00 | Updated Date 07/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 6.87 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-07-16 | When Before Market | Estimate 1.93 | Actual - |
Profitability
Profit Margin 28.41% | Operating Margin (TTM) 25.66% |
Management Effectiveness
Return on Assets (TTM) 8.84% | Return on Equity (TTM) 15.96% |
Valuation
Trailing PE 76.87 | Forward PE 68.03 | Enterprise Value 184780133013 | Price to Sales(TTM) 21.72 |
Enterprise Value 184780133013 | Price to Sales(TTM) 21.72 | ||
Enterprise Value to Revenue 21.2 | Enterprise Value to EBITDA 62.61 | Shares Outstanding 358417984 | Shares Floating 356260577 |
Shares Outstanding 358417984 | Shares Floating 356260577 | ||
Percent Insiders 0.52 | Percent Institutions 89.05 |
Upturn AI SWOT
Intuitive Surgical Inc
Company Overview
History and Background
Intuitive Surgical Inc. was founded in 1995. Its da Vinci Surgical System received FDA clearance in 2000, revolutionizing minimally invasive surgery. The company has since expanded its product line and global presence.
Core Business Areas
- Surgical Systems: Designs, manufactures, and markets the da Vinci surgical systems, enabling surgeons to perform minimally invasive procedures.
- Instruments and Accessories: Provides instruments, endoscopes, and accessories used with the da Vinci systems, generating recurring revenue.
- Services: Offers a range of services, including system maintenance, training, and extended warranties.
- Digital Solutions: Develops digital platforms and analytics to enhance surgical performance and outcomes.
Leadership and Structure
Gary S. Guthart is the CEO. The company has a structured organizational framework with functional departments, regional divisions, and a board of directors overseeing strategic decisions.
Top Products and Market Share
Key Offerings
- da Vinci Surgical System: A robotic surgical system that allows surgeons to perform complex procedures with greater precision, dexterity, and control. It has significant market share within the surgical robotics market, estimated to be above 70%. Competitors include Stryker (SYK), Medtronic (MDT), and Johnson & Johnson (JNJ).
- Instruments and Accessories: Includes a variety of specialized instruments and accessories designed for use with the da Vinci system. Revenue from these consumables is significant and recurring. Competitors also include the surgical arms of Stryker (SYK), Medtronic (MDT), and Johnson & Johnson (JNJ).
Market Dynamics
Industry Overview
The surgical robotics industry is experiencing substantial growth, driven by an increasing demand for minimally invasive procedures, technological advancements, and an aging population.
Positioning
Intuitive Surgical is the market leader in surgical robotics, holding a dominant market share due to its established da Vinci system, brand recognition, and extensive installed base. Its competitive advantages include its first-mover advantage, strong intellectual property portfolio, and robust training programs.
Total Addressable Market (TAM)
The total addressable market is estimated to be $50-$70 billion. Intuitive Surgical is well-positioned to capture a significant portion of this TAM, given its established market presence and continued innovation.
Upturn SWOT Analysis
Strengths
- Market leadership in surgical robotics
- Strong brand recognition and reputation
- Extensive installed base of da Vinci systems
- Recurring revenue from instruments and services
- Strong intellectual property portfolio
- High barriers to entry
Weaknesses
- High system cost
- Reliance on the da Vinci system
- Competition from emerging players
- Regulatory scrutiny
Opportunities
- Expanding applications for robotic surgery
- Growth in emerging markets
- Development of new instruments and accessories
- Integration of artificial intelligence and data analytics
- Partnerships and acquisitions
Threats
- Increasing competition from established medical device companies
- Pricing pressure
- Technological disruption
- Economic downturns
- Patent expirations
- Product liability lawsuits
Competitors and Market Share
Key Competitors
- SYK
- MDT
- JNJ
Competitive Landscape
Intuitive Surgical holds a dominant position with its da Vinci system. Competitors are emerging with their own robotic surgical systems, attempting to capture market share. The landscape is evolving, with increased emphasis on AI and data analytics.
Major Acquisitions
Schu00f6lly Fiberoptic GmbH
- Year: 2019
- Acquisition Price (USD millions): 190
- Strategic Rationale: This acquisition was meant to strengthen Intuitive Surgicalu2019s supply chain, enhance its capabilities in imaging technology, and increase control over key components used in its surgical systems.
Growth Trajectory and Initiatives
Historical Growth: Intuitive Surgical has experienced significant growth in revenue and profitability over the past decade, driven by the adoption of robotic surgery.
Future Projections: Analysts project continued growth for Intuitive Surgical, driven by expanding applications for robotic surgery and increasing demand in emerging markets.
Recent Initiatives: Recent initiatives include the launch of new da Vinci system models, expansion of its digital platform, and strategic acquisitions to enhance its product offerings.
Summary
Intuitive Surgical is a dominant player in the robotic surgery market with a strong financial profile and high growth potential. Its market leadership is built on its flagship da Vinci system and recurring revenue streams. The company should watch out for increasing competition and emerging alternative technologies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (10-K, 10-Q), Investor Presentations, Analyst Reports, Market Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and due diligence. Market share estimates are based on available data and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Intuitive Surgical Inc
Exchange NASDAQ | Headquaters Sunnyvale, CA, United States | ||
IPO Launch date 2000-06-13 | CEO & Director Dr. Gary S. Guthart Ph.D. | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 15638 | Website https://www.intuitive.com |
Full time employees 15638 | Website https://www.intuitive.com | ||
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. Intuitive Surgical, Inc. was incorporated in 1995 and is headquartered in Sunnyvale, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.